1/13
03:17 pm
beam
Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]
Low
Report
Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]
1/13
06:36 am
beam
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
Medium
Report
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
1/12
12:51 pm
beam
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
Low
Report
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
1/11
05:13 pm
beam
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
High
Report
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
1/11
05:00 pm
beam
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
High
Report
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
1/11
01:03 am
beam
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
High
Report
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
1/9
06:10 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
1/7
03:00 am
beam
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
1/5
12:43 pm
beam
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure [Yahoo! Finance]
Low
Report
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure [Yahoo! Finance]
1/5
07:20 am
beam
Cathie Wood's moves entering 2026: bets on gene-editing and genomics names, adds BEAM, TWST, NTLA [Seeking Alpha]
Low
Report
Cathie Wood's moves entering 2026: bets on gene-editing and genomics names, adds BEAM, TWST, NTLA [Seeking Alpha]
1/3
01:06 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at
Wall Street
Low
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at
Wall Street
12/31
11:14 am
beam
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? [Yahoo! Finance]
Low
Report
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? [Yahoo! Finance]
12/30
11:57 pm
beam
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene [Yahoo! Finance]
Medium
Report
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene [Yahoo! Finance]
12/30
07:42 am
beam
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? [Yahoo! Finance]
Low
Report
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? [Yahoo! Finance]
12/22
07:02 am
beam
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy [Yahoo! Finance]
Medium
Report
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy [Yahoo! Finance]
12/18
04:01 pm
beam
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
12/9
11:57 am
beam
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Low
Report
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
12/6
04:23 pm
beam
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential [Yahoo! Finance]
Low
Report
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential [Yahoo! Finance]
12/6
08:00 am
beam
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Low
Report
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
12/4
02:42 pm
beam
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]
Low
Report
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]
11/27
07:07 pm
beam
Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]
Low
Report
Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]
11/26
06:43 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
11/24
09:07 am
beam
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
11/18
08:09 am
beam
Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]
Low
Report
Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]
11/17
11:03 am
beam
Beam Therapeutics (NASDAQ:BEAM) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..